[Use of recombinant factor VIIa for the control of massive bleeding caused by uterine hypotonia in post-placental period].
We report our clinical opinion for recombinant activated factor VII (NovoSeven, Novo Nordisk, Copenhagen, Denmark) administration in puerperae with massive haemorrhage caused by uterine hypotonia. Four women with severe bleeding in post-placental period received NovoSeven in bolus IV. The blood loss and laboratory changes in hematology and haemostasis parameters are monitored. The right time of application and the mean effective dose of the medication are discussed. The bleeding was ceased in all cases. Decrease in values of Hb, Er and PTT was noted. The mean administered dose of 72 micrograms/kg BW was effective. The laboratory values showed tendency for improvement on the 24 hour after administration and normal levels on discharge. The use of recombinant factor VIIA in puerperae with severe bleeding in the postplacental period is effective and safe enough and could be an alternative to the extreme surgical procedures.
Tanchev
S
S
Platikanov
V
V
Markova
S
S
Slavov
N
N
Bogdanova
A
A
Dimitrova
D
D
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects; D005167:Factor VII / Q000008:administration & dosage / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D009123:Muscle Hypotonia / Q000150:complications*; D006473:Postpartum Hemorrhage / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D011247:Pregnancy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014599:Uterus / Q000098:blood supply*
D006490:Hemostatics; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa